Results 21 to 30 of about 6,111 (204)

Safety and Efficacy of Low-Dose Tirofiban Combined With Intravenous Thrombolysis and Mechanical Thrombectomy in Acute Ischemic Stroke: A Matched-Control Analysis From a Nationwide Registry

Frontiers in Neurology, 2021
Purpose: Tirofiban administration to acute ischemic stroke patients undergoing mechanical thrombectomy with preceding intravenous thrombolysis remains controversial.
Gaoting Ma, Shuo Li, Baixue Jia, Dapeng Mo, Ning Ma, Feng Gao, Xiaochuan Huo, Gang Luo, Anxin Wang, Yuesong Pan, Ligang Song, Xuan Sun, Xuelei Zhang, Liqiang Gui, Cunfeng Song, Ya Peng, Jin Wu, Shijun Zhao, Junfeng Zhao, Zhiming Zhou, Zhongrong Miao   +20 more
doaj   +1 more source

Safety and efficacy of low-dose and long-course tirofiban in large hemispheric infarction

Frontiers in Neurology, 2022
BackgroundThe clinical efficacy and safety of tirofiban in the treatment of large hemispheric infarction (LHI) remain controversial.MethodsThis study prospectively enrolled patients with acute LHI who were admitted to Putuo Hospital affiliated with ...
Yinqin Hu, Qian Xiao, Zhizhen Shi, Yangbo Hou, Zhen Chen, Jiwei Cheng, Guoyi Li   +6 more
doaj   +1 more source

Influence of tirofiban on stroke outcome after mechanical thrombectomy in acute vertebrobasilar artery occlusion

BMC Neurology, 2022
Background Even undergoing mechanical thrombectomy (MT), patients with acute vertebrobasilar artery occlusion (AVBAO) still have a high rate of mortality.
Xiding Pan, Mengyi Xu, Yuxiang Fei, Shiteng Lin, Yapeng Lin, Jianjun Zou, Jie Yang   +6 more
doaj   +1 more source

Efficacy and safety of tirofiban in patients with acute ischemic stroke without large-vessel occlusion and not receiving intravenous thrombolysis: A randomized controlled open-label trial

Journal of Neurorestoratology, 2022
ObjectiveTo investigate the effectiveness and safety of tirofiban in patients with acute ischemic stroke (AIS) without large-vessel occlusions and not receiving intravenous thrombolysis.MethodsOverall, 267 cases were included in the study (134 cases in ...
Yongpeng Yu, Yali Zheng, Xia Dong, Xiaohong Qiao, Yu Tao   +4 more
doaj   +1 more source

Platelet Function and Risk of Bleeding in Patients With Acute Coronary Syndrome Following Tirofiban Infusion

Frontiers in Pharmacology, 2019
Aim: To assess platelet (PLT) function and bleeding risks in patients with acute coronary syndrome after tirofiban infusion.Methods: Patients diagnosed with acute coronary syndrome from May 2016 to February 2018 in the Department of Cardiac Intensive ...
Xiaoye Li, Shuning Zhang, Zi Wang, Qiuyi Ji, Qibing Wang, Xiaoyu Li, Qianzhou Lv   +6 more
doaj   +1 more source

Efficacy and safety of tirofiban injection with intracranial stenting in early reocclusion due to intracranial atherosclerosis

Interdisciplinary Neurosurgery, 2022
Objective: We aimed to develop an optimal protocol for failed mechanical thrombectomy (MT) in cases of emergent large vessel occlusion (ELVO) with intracranial atherosclerosis (ICAS).
Yun Ho Noh, Ji Young Lee, Seok Mann Yoon, Yu Jin Ha, Jaewoo Chung, Jung Ho Ko, Dong Seong Shin, Jae-Min Ahn, Hyuk Jin Oh, Jai-Joon Shim, Man Ryul Lee, Jae Sang Oh   +11 more
doaj  

Are tirofiban and abciximab identical in efficacy? [PDF]

European Heart Journal, 2005
We read the paper by Mukherjee et al .1 on similar efficacy outcomes with tirofiban and ReoPro with a lot of interest and considerable reservations. The paper was hand-delivered to me by the representative of one of the drugs in the study with the proud claim that both drugs were equivalent.
openaire   +3 more sources

Statistical analysis for efficacy of tirofiban combined with ozagrel in the treatment of progressive cerebral infarction patients out of thrombolytic therapy time window

Clinics, 2021
OBJECTIVES: To investigate the safety and efficacy of combined tirofiban-ozagrel therapy for treating progressive stroke patients out of thrombolytic therapy time window.
Huiying Zhang, Lei Zheng
doaj   +1 more source

Tirofiban and emergency coronary surgery [PDF]

European Journal of Cardio-Thoracic Surgery, 2005
The final common pathway of platelet aggregation leading to coronary thrombosis involves cross-linking of platelet receptor glycoprotein IIb-IIIa by primarily fibrinogen. Glycoprotein IIb-IIIa antagonists are being increasingly used as adjunctive therapy during percutaneous coronary intevention, and have shown to reduce the risk of death and myocardial
openaire   +3 more sources

Clinical safety and possible efficacy of tirofiban in combination with intravenous thrombolysis by recombinant tissue plasminogen activator for early treatment of capsular warning syndrome (CWS)

Frontiers in Neuroscience, 2022
The purpose of this study was to assess the efficacy and safety of the combination of tirofiban with intravenous thrombolysis (IVT) in treating patients with capsular warning syndrome (CWS) who failed to respond to the treatment of intravenous ...
Yunzhu Liu, Shiyong Li, Dongdong Hao, Zhongping Zhang, Yongxin Yi, Jiayang Fang, Weizhi Lin, Min Zhang   +7 more
doaj   +1 more source